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Abstract
The increased understanding of the molecular basis of oral cancer has led to expectations that
correction of the genetic defects will lead to improved treatments. Nevertheless, the first clinical
trials for gene therapy of oral cancer occurred 20 years ago, and routine treatment is still not
available. The major difficulty is that genes are usually delivered by virus vectors whose effects are
weak and temporary. Viruses that replicate would be better, and the field includes many
approaches in that direction. If any of these are effective in patients, then gene therapy will become
available in the next few years. Without significant advances, however, the treatment of oral cancer
by gene therapy will remain as remote as the legendary pot of gold at the end of the rainbow.
Introduction
Recent research into oral cancer has revealed a large
amount of information about the nature of the disease. The
details of many of the genetic changes are now available,
raising the possibility that they could be reversed and that
the growth of the tumors could be prevented. At the same
time, information has accumulated about the oral viruses
that could be used as delivery systems for the new treat-
ments. Efforts to treat oral cancer in this way have thus been
in progress for over 20 years. Despite this there is still no sci-
entific evidence that oral cancer in humans can be managed
by any form of genetic manipulation, or by the use of any
viral vectors. Nevertheless, interest in the subject is main-
tained by promising advances in animals and by the unfor-
tunate lack of progress in competing fields such as
chemotherapy. This review surveys the most promising
aspects of gene therapy that have emerged in the last two
decades, and attempts to identify the areas in which the
most effort should be invested.
Approaches to gene therapy
Replacement of defective genes
In many cases of oral cancer some genes are defective, and
replacing them with a normal variant is an obvious thera-
peutic strategy. The gene that has attracted most attention
is p53, which is defective in about 50% of cases. Efforts to
replace p53 have existed for 20 years, starting in cell cul-
ture and advancing through animal studies to phase I clin-
ical trials [1]. The results have shown some promise in
animals and the virus vector is well tolerated in humans.
No results from adequately controlled trials are yet avail-
able. It is also unclear if the non-replicating virus vector is
transducing a suitable proportion of tumor cells, or
whether the normal p53 gene can indeed substitute func-
tionally for a mutated gene in a tumor.
Another approach to therapy consists of suppressing
genes that have become defective or are overexpressed.
There are numerous examples of such genes, including
regulators of apoptosis [2], genes from papillomaviruses
[3], and the gene that encodes the receptor for Epidermal
Growth Factor [4]. Methods of suppression have used
antisense RNA, ribozymes, and siRNA, and delivery meth-
ods have included direct transfer, lipofection, and adeno-
virus vectors [5]. These studies have succeeded in reducing
the growth and the malignant characteristics of tumor
cells in vitro, but not in animals or patients.
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Suicide gene therapy
Many anti-cancer drugs can be delivered as inactive pre-
cursors, and be activated by enzymes that are encoded by
specific genes. If such genes can be provided to tumor cells
only, then systemic delivery of the drug precursor could
lead to an effective anti-tumor effect without side effects
in other tissues. The most popular example of this
approach has been to provide the gene for thymidine
kinase from herpes simplex virus type 1 (HSV-1) to cells
or tumors, followed by the pro-drug ganciclovir [6].
Another example is the gene CYP2B1 which activates
cyclophosphamide to a toxic form [7]. This approach can
kill oral cancer cells efficiently in culture and reduce the
growth of tumors in animals [8] but no human clinical
trial has demonstrated its efficacy.
Viral Vectors
Although there are several non-viral methods of transfer-
ring genes to oral cancer cells, it is generally accepted that
viruses provide the most efficient form of transfer. Early
experiments used viruses that were mutated so as to pre-
vent their replication, but more recent work has focused
on viruses that can replicate in specific tumor cells.
Non replicating viral vectors
Early efforts at gene transfer were impeded by concerns
that the virus vectors might cause infections or malignan-
cies in the recipients. To prevent this, the vectors were pre-
vented from replicating by removal of essential genes. The
resulting viruses were still able to transfer marker genes to
cells, but since they did not spread the markers were soon
lost [9,10]. Clearly, if the marker was replaced by a thera-
peutic gene the therapeutic effect would be limited to the
site of viral injection, which can only be a small propor-
tion of a tumor.
Conditionally replication-competent vectors
A more efficient way to deliver toxic or therapeutic genes
is in a virus that can replicate in a tumor cell but can not
replicate in any other kind of cell. In the case of HSV-1 this
can be achieved by deletion of viral genes that contribute
to either neurotoxicity or to replication in normal cells,
such as the genes gamma-1-34.5 and ribonucleotide
reductase respectively. A viral mutant that lacks both of
these genes and has been widely tested is named G207
[11]. Other mutants have been generated by changes in
the genes UL56 or UL24 [12]. As a result of multiple dele-
tions such as these, viral strains exist that can be injected
directly to brain of herpes-susceptible primates without
development of an infection [13]. Herpes viruses with
these deletions can inhibit the growth of oral cancer cells
that are growing as tumors in mice [14], but are not effec-
tive with every cell line [15].
Adenoviruses can also be manipulated to limit the tissues
in which they replicate. An early example was the adeno-
virus Onyx015, which has a deletion of the E1B gene that
increases its tumor specificity. This virus was tested in
early clinical trials, and appeared to show a therapeutic
effect in about 14% of patients [16]. Further clinical tests
were discontinued, but the virus is available for treating
oral cancer in China [17]. This probably represents the
only example of gene therapy for any condition that cur-
rently exists outside of a clinical trial.
A different approach to change the tissue specificity of a
virus is to replace the promoter of an essential gene with a
promoter that is particularly active in specific tumors.
Gene promoters that have been tested include those from
liver [18], from soft tissues and bone [19] and those that
respond to specific oncogenes [20,21]. For oral cancer the
only tumor-related gene promoter that appears to have
been used is one derived from a human papillomavirus.
Papillomavirus promoters show a high level of specificity
for oral cancer cells [22] and a strain of HSV-1 in which
replication is driven by a papillomavirus promoter is
under evaluation [23].
Safety of viral vectors
Although earlier concerns about the safety of viral vectors
are now seen as having been exaggerated, there are still
potential side effects. Widespread publicity has been given
to a fatal reaction to a high dose of adenovirus in a trial of
gene therapy for a liver enzyme deficiency [24], as well as
to the unfortunate induction of leukemia in a small group
of children who were being treated for a congenital
immune deficiency [25]. Overall, however, given the large
number of patients who have been entered into various
gene therapy clinical trials, the use of viral vectors appears
to be extremely safe.
Enhancement of viral virulence
The effectiveness of conditionally-replicating viruses can
be increased still further by arming them with genes that
encode toxic functions. Recent examples of such genes
include those that encode cytokines such as GM-CSF [26]
and those that specify formation of syncytia [27]. The
addition of the gene for interleukin 12 has been found to
increase the effect of treating oral cancer in mice with sui-
cide gene therapy [8].
Immune suppression
All of the viruses that have been used for experimental
gene therapy are as antigenic as the wild type viruses, and
thus they are can stimulate immune responses that affect
their function. To prevent this, various efforts have been
made to suppress immunity and increase the effects of the
virus.Head & Neck Oncology 2009, 1:7 http://www.headandneckoncology.org/content/1/1/7
Page 3 of 5
(page number not for citation purposes)
Cyclophosphamide increases the anti-tumor effect of
HSV-1 in rodent models of glioblastoma multiforme, and
this has been attributed to reductions in complement and
natural antibody which normally act together to reduce
the replication of the virus [28,29]. In tumors, cyclophos-
phamide can reduce infiltration by phagocytic cells and
this increases the proportion of tumor cells that are
infected [30]. In some situations, in contrast, the immune
response might be actually helpful in the elimination of
infected tumors. Cyclophosphamide actually reduced the
anti-tumor effect of the virus in a rodent model of malig-
nant melanoma [31].
For oral cancers there are few data available on the role of
the immune response in the effects of oncolytic viruses.
We have tested the effects of HSV-1 on oral cancers in
strains of mice that lacked several different components of
innate and acquired immunity. The virus was no more
effective in any strain [32], which implies only a minor
role for anti-viral immunity in oral cancer.
Tissue permeabilization
The failure of viruses to spread through solid tumors
might be due, in part, to the density of the tissue. In that
case, any approach that loosens the tissue might allow
more of the tumor to become infected. The injection of
proteases such as collagenase or trypsin into experimental
glioblastomas before injection of an adenovirus has led to
better therapeutic result in one study [33]. The enzyme
hyaluronidase also increases the anti-tumor effect of ade-
noviruses [34] and collagenase has been reported to allow
oncolytic HSV-1 to infect more cells in a malignant
melanoma [35]. Similarly, the enzyme relaxin can digest
fibers in connective tissue and it is possible to clone the
gene that encodes relaxin into adenoviruses [36]. Another
approach to induce oncolytic HSV-1 to spread through a
tumor more effectively is to induce apoptosis in the tumor
cells [37] although premature apoptosis could also inhibit
the replication of the virus.
Concurrent therapeutic drugs
It is a standard practice in cancer therapy to combine
two or more agents, because this often produces an
additive or synergistic anti-tumor effect. If the side-
effects of the agents are different, then this approach
can minimize the unwanted effects of treatment. A sim-
ilar approach has been investigated in the use of onco-
lytic viruses (Table 1) [12,38-46]. In animal models,
drugs that have increased the anti-oral cancer effects of
replicating viruses include cisplatin [38,47], Hexameth-
ylene bisacetamide [43] and cyclophosphamide [42]. In
a clinical trial of the adenovirus Onyx015 for treatment
of oral cancer, the virus was given in combination with
cisplatin or 5-FU [48].
Surprisingly, there is little or no acknowledgement among
those who have used it that the combination of viruses
and cytotoxic drugs should, in fact, be expected to fail.
Viruses almost always replicate better in cells that are
healthy and growing rapidly. Therefore any cytotoxic drug
should reduce the effects of a virus rather than enhance
them, and combinations should be less effective than
either agent alone. One reason that such combinations
can be effective might be that they have been demon-
strated only in mutant viruses that lack some essential
function. The drug might stimulate the tumor cells to
express that function and complement the viruses defi-
ciency. For example, some drugs induce DNA repair func-
tions including the expression of the gene GADD34 that
can substitute for the viral gene gamma-1-34.5 [49]. In
other cases the mode of enhancement is not known. Also
unclear is whether any drug can increase the effects of
attenuated mutants to the extent that they become more
potent than the equivalent wild-type virus. Even wild-type
viruses have only limited effects on oral cancers [42] and
an anti-tumor effect that is better than that of the wild-
type virus is necessary if oncolytic viruses are to be truly
successful.
Table 1: Drugs that increase the effects of oncolytic viruses
Drug Enhanced anti-tumor effect in vivo1 Reference2
Cisplatin Yes – Oral cancer [38]
Cyclophosphamide Yes – Oral cancer [42]
Estrogen No [45]
5-FU No [40]
Gemcitabine No [40]
Hexamethylene bisacetamide Yes – Oral cancer [43]
Mitomycin C Yes – Gastric cancer [46]
N-acetylcysteine No [44]
Trichostatin A No [41]
Vincristine Yes – Rhabdomyosarcoma [39]
1 Although each of the drugs shown here has been found to increase the growth-inhibiting effects of adenovirus or HSV-1-vectors in cell culture, 
only some have been shown to increase the anti-tumor effect in animal models.
2 Only one representative reference is shown for each drug, although other laboratories have reported similar findings in many cases.Head & Neck Oncology 2009, 1:7 http://www.headandneckoncology.org/content/1/1/7
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The future of gene therapy
Many approaches to gene therapy of oral cancer now exist
in the laboratory, and some have been tested in human
patients. However, there seems to be no evidence so far
that any gene therapy approach can be expected to be as
good or better than conventional approaches to treat-
ment. This is largely due to the lack of any model in which
the virus replicates and spreads until the entire tumor is
infected and all cells are destroyed. The field, nonetheless,
continues to advance and new approaches are continually
being brought forward for evaluation. Thus we can expect
much more data to emerge over the next few years.
Gene therapy is sometimes seen as the pot of gold at the
end of the rainbow. However, it must be remembered that
not only are rainbows intangible, but the very existence of
leprachauns and the pot of gold that they hide at the end
is seriously doubted. Whether gene therapy belongs in the
same category is unknown and significant improvements
are needed to prevent the topic from fading into the cate-
gory of appealing legends.
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